ICODAAS 2027
People

Chair, Committee and Team

The people responsible for the academic quality and the organisation of ICODAAS 2027, organised by ISO LONDON LIMITED on behalf of the Northern Cyprus Prime Ministry Anti-Drug Commission.

Photograph of Prof Dr Dr (h.c.) Marilyn A. Huestis
Conference Chair and Keynote Speaker

Prof Dr Dr (h.c.) Marilyn A. Huestis

PhD, Doctor Honoris Causa, University of Helsinki

Senior Fellow, Institute on Emerging Health Professions, Thomas Jefferson University; President, Huestis & Smith Toxicology, LLC; retired Chief, Chemistry and Drug Metabolism, National Institute on Drug Abuse, NIH.

Photograph of Dr Zafer Bekiroğulları
Project Coordinator

Dr Zafer Bekiroğulları

CPsychol, AFBPsS, FCBPis, PhD

ESPAD Northern Cyprus Project Coordinator; Chair, International Cognitive and Behavioural Psychotherapies Society (CBPis).

ORCID 0000-0003-1549-7171

On behalf of

Northern Cyprus Prime Ministry Anti-Drug Commission
KKTC Başbakanlık Uyuşturucu ile Mücadele Komisyonu

The Commission leads the national response to drugs in Northern Cyprus, including prevention and research such as the ESPAD school survey. ICODAAS is organised on its behalf to bring international evidence on prevention, treatment and policy together with practitioners from the region.

ICODAAS 2027 Scientific Committee

The Scientific Committee for 2027 is being formed. We list a member here only after they have agreed in writing to serve for this edition, so the names you see are always current and accurate.

Every abstract and full paper is reviewed by qualified academics with expertise in the topic, who declare any conflict of interest. Committee members and reviewers are listed in the conference proceedings.

Conference secretariat

Conference secretariat
info@icodaas.com
Abstracts and review
submissions@icodaas.com
Registration and invoices
registration@icodaas.com

Our staff are committed to providing a professional service and have the right to work without fear of abuse or intimidation. We kindly ask that all correspondence be respectful and professional.

Reviewer integrity

Committee members and reviewers declare any conflict of interest, including industry funding, and do not review work by colleagues from their own institution or by recent co-authors. Committee members who submit their own papers go through the same review as every other author.